Skip to main content
IVVD
NASDAQ Life Sciences

Invivyd Q2 Loss Widens; Going Concern Doubt and Nasdaq Delisting Notice Disclosed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.661
Mkt Cap
$202.012M
52W Low
$0.483
52W High
$3.07
52W Position info
37% above low
Off High info
78% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

IVVD sits 37% above its 52-week low of $0.483.

Summary

Invivyd's Q2 loss widened to $44.4M, and the 10-Q discloses going concern doubt, a Nasdaq delisting notice, and the upcoming loss of its only authorized product's EUA.


Key Events · Earnings and Guidance · IVVD

  • Q2 Net Loss Misses Estimates

    Net loss of $44.4 million, or $0.14 per share, versus consensus of $0.11 per share. Revenue was $14.3 million, up 21% year-over-year.

  • Going Concern Doubt

    Management concluded substantial doubt about ability to continue as a going concern, with cash and cash equivalents of $160.1 million insufficient to fund operations beyond one year from the filing date.

  • Nasdaq Delisting Notice

    Received July 23, 2026, for closing bid price below $1.00 for 30 consecutive business days. Company has until January 19, 2027 to regain compliance.

  • PEMGARDA EUA Termination

    HHS declaration termination will end PEMGARDA's emergency use authorization on June 29, 2027, eliminating the company's only authorized product revenue unless full approval is obtained.


Analysis · IVVD · Life Sciences

Invivyd reported a Q2 net loss of $44.4 million, missing consensus, and disclosed substantial doubt about its ability to continue as a going concern with less than one year of cash runway. The company also revealed a Nasdaq delisting notice received July 23, 2026, and the termination of its PEMGARDA EUA effective June 29, 2027. These are critical survival risks for a company with a market cap around $202 million.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IVVD was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202M. The 52-week trading range was $0.48 to $3.07. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IVVD - Latest Insights

IVVD
Sep 29, 2026, 7:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9635
Real-time Price: $0.5441 info
Change: -$0.4194 (-44%) info
Market Cap: $160.378M info
IVVD
Sep 29, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.5441 info
Change: -$0.6157 (-53%) info
Market Cap: $160.378M info
IVVD
Sep 01, 2026, 7:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9303
Real-time Price: $0.5441 info
Change: -$0.3862 (-42%) info
Market Cap: $160.378M info
IVVD
Aug 13, 2026, 4:25 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.666
Real-time Price: $0.5441 info
Change: -$0.1219 (-18%) info
Market Cap: $160.378M info
IVVD
Jul 24, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6114
Real-time Price: $0.5441 info
Change: -$0.0673 (-11%) info
Market Cap: $160.378M info